Clinical trial
Vorinostat and Palliative Radiotherapy
NCT00455351 · Oslo University Hospital, Other · Completed
Key facts
| NCT number | NCT00455351 |
|---|---|
| Title | Vorinostat and Palliative Radiotherapy |
| Official title | Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors. |
| Acronym | PRAVO |
| Lead sponsor | Oslo University Hospital, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pelvic Cancer, Radiotherapy |
| Intervention type | Drug |
| Interventions | Vorinostat |
| Enrollment | 15 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Apr 3, 2007 |
| Last update posted | May 8, 2023 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: